- Home
- ROIV vs EDU Comparison
ROIV vs EDU Comparison
Compare ROIV & EDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | EDU |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United Kingdom | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 8.7B |
| IPO Year | 2021 | 2006 |
Fundamental Metrics
Financial Performance| Metric | ROIV | EDU |
|---|---|---|
| Price | $38.88 | $54.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 20 |
| Target Price | $50.00 | ★ $70.48 |
| AVG Volume (30 Days) | ★ 6.8M | 802.4K |
| Earning Date | 11-09-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 3.71% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,260,000.00 | N/A |
| Revenue This Year | $593.33 | $18.78 |
| Revenue Next Year | $648.48 | $12.73 |
| P/E Ratio | ★ N/A | $24.75 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.79 | $44.25 |
| 52 Week High | $42.50 | $64.97 |
Technical Indicators
Market Signals| Indicator | ROIV | EDU |
|---|---|---|
| Relative Strength Index (RSI) | 59.57 | 49.29 |
| Support Level | $33.11 | $54.10 |
| Resistance Level | $42.50 | $59.24 |
| Average True Range (ATR) | 1.52 | 1.67 |
| MACD | 0.28 | -0.31 |
| Stochastic Oscillator | 98.33 | 50.26 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in livestreaming e-commerce.